Clinical Trial Update: Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tepotinib with cetuximab in left-sided RAS/BRAF wild-type metastatic colorectal cancer was terminated; results posted previously.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Cetuximab (cetuximab)
• Tepotinib (tepotinib)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Colorectal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2022-12-22